Loading...
Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma
Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...
Saved in:
| Published in: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7016578/ https://ncbi.nlm.nih.gov/pubmed/31877859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|